Daily MedNews
Printable Version   Email to a friend

Last of Woolly Mammoths Had North American Roots

FRIDAY, Sept. 5 -- The last woolly mammoths had exclusively North American genetic roots, according to Canadian researchers who say their finding challenges conventional wisdom and could generate controversy.

Woolly mammoths lived between 40,000 and 4,000 years ago.

"Scientists have always thought that because mammoths roamed such a huge territory -- from Western Europe to Central North America -- that North American wooly mammoths were a sideshow of no particular significance to the evolution of the species," Hendrik Poinar, an associate professor in the departments of anthropology, and pathology and molecular medicine at McMaster University in Hamilton, Ontario, said in a university news release.

Poinar and colleague Regis Debruyne collected and analyzed DNA samples from mammoth remains found in Siberia and in North America.

About 5 million to 6 million years ago, an early mammoth species migrated north into China, Siberia and, eventually, North America, which gave rise to a new mammoth known as the Columbian mammoth, Poinar explained. Much later, a cold-adapted form called the woolly mammoth evolved in Siberia and eventually crossed over into North America. The Siberian genetic forms then began to disappear and were replaced by North American migrants.

"Migrations over Beringia [the land bridge that once spanned the Bering Strait] were rare; it served as a filter to keep eastern and western groups or populations of woollies apart," Poinar said. "However, it now appears that mammoths established themselves in North America much earlier than presumed, then migrated back to Siberia, and eventually replaced all pre-existing haplotypes of mammoths."

"Like paleontologists, molecular biologists have long been operating under a geographic bias," Debruyne said in the McMaster University news release. "For more than a century, any discussion on the woolly mammoth has primarily focused on the well-studied Eurasian mammoths. Little attention was dedicated to the North American samples, and it was generally assumed their contribution to the evolutionary history of the species was negligible. This study certainly proves otherwise."

The study was published in the September issue of Current Biology.

More information

The Academy of Natural Sciences has more about the woolly mammoth.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 20, 2008
Audience: Consumers, endocrinological healthcare professionals [Posted 11/20/2008] Animas Corporation and FDA informed consumers...
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...